Without the use of ESAs, the administration of HIF-PH inhibitors can increase Hgb levels in patients with CKD, which implies that the pathogenesis of renal anemia is not only caused by insufficient EPO production but also the defective translation of the EPO gene [131]. Here, EPO is linked to chronic kidney disease.